Sherie Carnegie, DO
Family Medicine · Downey, CANPI 1821013772
Payments from drug & device makers
Across 526 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Amgen$838
- AstraZeneca$584
- Baxter Healthcare$580
- Lilly USA, LLC$482
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,03391%
- Education$2042%
- Other$5807%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,236 |
| Novo Nordisk | 104 | $1,111 |
| Amgen(2 entities) | 55 | $838 |
| AstraZeneca | 31 | $584 |
| Baxter Healthcare | 1 | $580 |
| Lilly USA, LLC | 23 | $482 |
| GSK | 24 | $468 |
| Boehringer Ingelheim | 14 | $361 |
| Mannkind Corporation | 32 | $347 |
| Amarin Pharma, Inc. | 19 | $327 |
| Pfizer | 23 | $264 |
| Merck | 14 | $254 |
| Astellas Pharma US Inc | 7 | $254 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $178 |
| Dexcom, Inc. | 6 | $173 |
| Bayer | 8 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $157 |
| Johnson & Johnson | 8 | $154 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Radius Health, Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 5 | $80 |
| Novartis | 3 | $80 |
| Scilex Pharmaceuticals Inc. | 3 | $67 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 1 | $34 |
| Averitas Pharma Inc. | 1 | $32 |
| Abbott | 2 | $32 |
| Lundbeck LLC | 1 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Smith+Nephew | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Lupin Inc. | 1 | $19 |
| Cequr Corporation | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $13 |
How this compares
$8,817 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $145,085 |
| RybelsusSemaglutide | 79 | $136,927 |
| JardianceEmpagliflozin | 96 | $101,245 |
| OzempicSemaglutide | 84 | $83,659 |
| JanuviaSitagliptin Phosphate | 87 | $81,479 |
| FarxigaDapagliflozin Propanediol | 64 | $68,016 |
| XifaxanRifaximin | 14 | $47,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $44,484 |
| KerendiaFinerenone | 40 | $43,555 |
| RexultiBrexpiprazole | 27 | $37,819 |
| LinzessLinaclotide | 37 | $27,079 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $18,955 |
| EntrestoSacubitril/Valsartan | 14 | $18,468 |
| XareltoRivaroxaban | 22 | $18,182 |
| TrulicityDulaglutide | 12 | $18,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,111 | $220,586163 claims |
| PfizerEliquis, Premarin | $264 | $149,168174 claims |
| Boehringer IngelheimJardiance | $361 | $101,24596 claims |
| MerckJanuvia, Steglatro | $254 | $88,191102 claims |
| AstraZenecaFarxiga | $584 | $68,01664 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $468 | $60,05270 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $178 | $47,81114 claims |
| BayerKerendia | $172 | $43,55540 claims |
| AbbVieLinzess, Ubrelvy | $1,236 | $39,23049 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $87 | $37,81927 claims |
| NovartisEntresto | $80 | $18,46814 claims |
| Johnson & JohnsonXarelto | $154 | $18,18222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Downey
- Kevin OeiDowney$4.2M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.